Dupilumab for prurigo nodularis: Case series and review of the literature
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Dupilumab for prurigo nodularis : Case series and review of the literature. / Holm, Jesper Gronlund; Agner, Tove; Sand, Carsten; Thomsen, Simon Francis.
I: Dermatologic Therapy, Bind 33, Nr. 2, e13222, 2020.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dupilumab for prurigo nodularis
T2 - Case series and review of the literature
AU - Holm, Jesper Gronlund
AU - Agner, Tove
AU - Sand, Carsten
AU - Thomsen, Simon Francis
PY - 2020
Y1 - 2020
N2 - Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.
AB - Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.
KW - anti-IL-4
KW - biologics
KW - dupilumab
KW - prurigo nodularis
U2 - 10.1111/dth.13222
DO - 10.1111/dth.13222
M3 - Review
C2 - 31917498
VL - 33
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 2
M1 - e13222
ER -
ID: 237323748